Last Day of Dealings on AIM

e-Therapeutics plc

08 May 2024

 

 

e-therapeutics plc  

("e-therapeutics" or "ETX" or the "Company") 

Last Day of Dealings on AIM

London, UK, 8 May 2024 - e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, provides a further update with regards to the cancellation of admission of the Company's ordinary shares to trading on AIM (the "Cancellation"), as originally announced on 10 April 2024 and as approved by shareholders at the general meeting held on 29 April 2024.

Shareholders are reminded that the last day of trading in ETX's ordinary shares on AIM is today, 8 May 2024. Cancellation will become effective at 7:00a.m. on 9 May 2024.

Following Cancellation, shareholders are encouraged to sign up to the Company's email news alerts via the e-therapeutics website to remain up to date with the Company's developments as we continue to advance our portfolio and target opportunities as a private company. The Company will maintain its shareholder communications email address - [e-mail] - and investors wishing to enter into dialogue with the Company are encouraged to email that address.

Dealing Arrangements

The Company's ordinary shares will be admitted to trading on the JP Jenkins securities matching platform from 9 May 2024. 

JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00B2823H99), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/e-therapeutics-plc/).

The provision of the matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility as well as the composition of the Company's register of members and the costs to the Company and shareholders.

Following Cancellation, SP Angel Corporate Finance LLP will cease to act as nominated adviser and corporate broker to the Company.

Enquiries 

e-therapeutics plc
Ali Mortazavi, CEO                                           Timothy Bretherton, CFO	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)  JP Jenkins Limited Matched Bargain Facility Veronika Oswald	Tel: [phone]

About e-therapeutics plc 

e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover and develop life-transforming medicines. ETX's proprietary RNAi chemistry platform, GalOmic™, enables generation of specific, potent, and durable siRNA therapeutics for effective silencing of novel gene targets in hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. HepNet™ encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design. The Company has specialist expertise and a robust position in applying computation to biology. Its computational approaches have been extensively validated through generation of data from pipeline programs and successful drug discovery collaborations with biopharma companies, such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.

Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need. The Company has generated positive proof-of-concept data on preclinical assets in metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia, and cardiometabolic disease, further validating its computationally enhanced approach to research and development. ETX is currently progressing lead assets ETX-312 for MASH and ETX-407 for dry AMD through IND-enabling studies and towards the clinic.

 

END